Pleiotropic effects of ezetimibe: Do they really exist?

European Journal of Pharmacology

Volumn 633, Issue 1-3, 2010, Pages 62-70

  Kalogirou, Michalis ^a   Tsimihodimos, Vasilis ^a   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Endothelial function; Ezetimibe; Inflammatory marker; Insulin resistance; Lipoprotein subfraction; Pleiotropic effect

Indexed keywords

ADIPOCYTOKINE; APOLIPOPROTEIN; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TETRAHYDROLIPSTATIN;

ADD ON THERAPY; AORTA ATHEROSCLEROSIS; APHERESIS; ARTERY OCCLUSION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FATTY LIVER; HEART FAILURE; HEPATOMEGALY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID ABSORPTION; LIPID OXIDATION; LOW DRUG DOSE; METABOLIC SYNDROME X; MORTALITY; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PLEIOTROPY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RHEUMATOID ARTHRITIS; THROMBOCYTE AGGREGATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPID METABOLISM; PLATELET AGGREGATION; TREATMENT OUTCOME;

EID: 77949917890     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.003     Document Type: Review

References (109)

1. Altmann S.W., Davis H.R., Zhu L.J., Yao X., Hoos L.M., Tetzloff G., Iyer S.P., Maguire M., Golovko A., Zeng M., Wang L., Murgolo N., Graziano M.P. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
2. Araújo D.B., Bertolami M.C., Ferreira W.P., Abdalla D.S., Faludi A.A., Nakamura Y., Bricharello L.P. Pleiotropic effects with equivalent LDL-cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe co-administration. J. Cardiovasc. Pharmacol. 2009, Electronic publication ahead of print.
3. Assmann G., Cullen P., Erbey J., Ramey D.R., Kannenberg F., Schulte H. Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Munster (PROCAM) study. Nutr. Metab. Cardiovasc. Dis. 2006, 16:13-21.
4. Athyros V.G., Kakafika A.I., Tziomalos K., Karagiannis A., Mikhailidis D.P. Pleiotropic effects of statins-clinical evidence. Curr. Pharm. Des. 2009, 15:479-489.
5. Ballantyne C.M., Abate N., Yuan Z., King T.R., Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am. Heart J. 2005, 149:464-473.
6. Ballantyne C.M., Hoogeveen R.C., Bang H., Coresh J., Folsom A.R., Heiss G., Sharrett A.R. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109:837-842.
7. Bays H.E., Moore P.B., Drehobl M.A., Rosenblatt S., Toth P.D., Dujovne C.A., Knopp R.H., Lipka L.J., Lebeaut A.P., Yang B., Mellars L.E., Cuffie-Jackson C., Veltri E.P. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin. Ther. 2001, 23:1209-1230.
8. Bays H.E., Ose L., Fraser N., Tribble D.L., Quinto K., Reyes R., Johnson-Levonas A.O., Sapre A., Donahue S.R. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin. Ther. 2004, 26:1758-1773.
9. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 2003, 23:168-175.
10. Bulut D., Hanefeld C., Bulut-Streich N., Graf C., Mugge A., Spiecker M. Endothelial function in the forearm circulation of patients with the metabolic syndrome-effect of different lipid-lowering regimens. Cardiology 2005, 104:176-180.
11. Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 2003, 11:1278-1289.
12. Catapano A., Brady W.E., King T.R., Palmisano J. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr. Med. Res. Opin. 2005, 21:1123-1130.
13. Dagli N., Yavuzkir M., Karaca I. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 2007, 30:230-235.
14. Davidson M.H., Ballantyne C.M., Kerzner B., Melani L., Sager P.T., Lipka L., Strony J., Suresh R., Veltri E. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int. J. Clin. Pract. 2004, 58:746-755.
15. Davies J.P., Levy B., Ioannou Y.A. Evidence for a Niemann-Pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics 2000, 65:137-145.
16. Davis H.R., Compton D.S., Hoos L., Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler. Thromb. Vasc. Biol. 2001, 21:2032-2038.
17. Derdemezis C., Filippatos T., Tselepis A., Mikhailidis D., Elisaf M. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert. Opin. Pharmacother. 2008, 9:1829-1837.
18. Deushi M., Nomura M., Kawakami A., Haraguchi M., Ito M., Okazaki M., Ishii H., Yoshida M. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007, 581:5664-5670.
19. Dietrich T., Hucko T., Bourayou R., Jahnke C., Paetsch I., Atrott K., Stawowy P., Gräfe M., Klein C., Schnackenburg B., Fleck E., Graf K. High resolution magnetic resonance imaging in atherosclerotic mice treated with ezetimibe. Int. J. Cardiovasc. Imaging 2009, 25:827-836.
20. Dujovne C.A., Ettinger M.P., McNeer J.F., Lipka L.J., LeBeaut A.P., Suresh R., Yang B., Veltri E.P. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol. 2002, 90:1092-1097.
21. Efrati S., Averbukh M., Dishy V., Faygenzo M., Friedensohn L., Golik A. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur. J. Clin. Pharmacol. 2007, 63:113-121.
22. Egashira K., Hirooka Y., Kai H., Sugimachi M., Suzuki S., Inou T., Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994, 89:2519-2524.
23. Ensign W., Hill N., Heward C.B. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin. Chem. 2006, 52:1722-1727.
24. Farnier M., Freeman M.W., Macdonell G., Perevozskaya I., Davies M.J., Mitchel Y.B., Gumbiner B. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 2005, 26:897-905.
25. Fichtlscherer S., Schmidt-Lucke C., Bojunga S., Rossig L., Heeschen C., Dimmeler S., Zeiher A.M. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur. Heart J. 2006, 27:1182-1190.
26. Fleg J.L., Mete M., Howard B.V., Umans J.G., Roman M.J., Ratner R.E., Silverman A., Galloway J.M., Henderson J.A., Weir M.R., Wilson C., Stylianou M., Howard W.J. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J. Am. Coll. Cardiol. 2008, 52:2198-2205.
27. Fliser D., Kronenberg F., Kielstein J.T., Morath C., Bode-Boger S.M., Haller H., Ritz E. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J. Am. Soc. Nephrol. 2005, 16:2456-2461.
28. Garcia-Calvo M., Lisnock J., Bull H.G., Hawes B.E., Burnett D.A., Braun M.P., Crona J.H., Davis H.R., Dean D.C., Detmers P.A., Graziano M.P., Hughes M., Macintyre D.E., Ogawa A., O'neill K.A., Iyer S.P., Shevell D.E., Smith M.M., Tang Y.S., Makarewicz A.M., Ujjainwalla F., Altmann S.W., Chapman K.T., Thornberry N.A. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8132-8137.
29. Gazi I.F., Daskalopoulou S.S., Nair D.R., Mikhailidis D.P. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr. Med. Res. Opin. 2007, 23:2183-2192.
30. Gazi I.F., Mikhailidis D.P. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin. Ther. Targets 2006, 10:851-866.
31. Ge L., Wang J., Qi W., Miao H.H., Cao J., Qu Y.X., Li B.L., Song B.L. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab. 2008, 7:508-519.
32. Geiss H.C., Otto C., Parhofer K.G. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Metabolism 2006, 55:599-604.
33. Gomez-Garre D., Munoz-Pacheco P., Gonzalez-Rubio M., Aragoncillo P., Granados R., Fernandez-Cruz A. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br. J. Pharmacol. 2009, 156:1218-1227.
34. Gonzalez-Ortiz M., Martinez-Abundis E., Kam-Ramos A.M., Hernandez-Salazar E., Ramos-Zavala M.G. Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc. Drugs Ther. 2006, 20:143-146.
35. Gordon T., Kannel W.B., Castelli W.P., Dawber T.R. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch. Intern. Med. 1981, 141:1128-1131.
36. Gounari P., Tousoulis D., Antoniades C., Kampoli A.M., Stougiannos P., Papageorgiou N., Roulia G., Stefanadi E., Siasos G., Tsioufis C., Stefanadis C. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. Int. J. Cardiol. 2009.
37. Gouni-Berthold I., Berthold H.K., Chamberland J.P., Krone W., Mantzoros C.S. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin. Endocrinol. 2008, 68:536-541.
38. Gouni-Berthold I., Berthold H.K., Gylling H., Hallikainen M., Giannakidou E., Stier S., Ko Y., Patel D., Soutar A.K., Seedorf U., Mantzoros C.S., Plat J., Krone W. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis 2008, 198:198-207.
39. Greenberg M.E., Smith J.D., Sehayek E. Moderately decreased cholesterol absorption rates are associated with a large atheroprotective effect. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1745-1750.
40. Heron M. Deaths: leading causes for 2004. Natl. Vital Stat. Rep. 2007, 56:1-95.
41. Hussein O., Minasian L., Itzkovich Y., Shestatski K., Solomon L., Zidan J. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br. J. Clin. Pharmacol. 2008, 65:637-645.
42. Kalogirou M., Tsimihodimos V., Gazi I., Filippatos T., Saougos V., Tselepis A.D., Mikhailidis D.P., Elisaf M. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr. Med. Res. Opin 2007, 23:1169-1176.
43. Kalogirou M., Tsimihodimos V., Saougos V., Lagos K., Tselepis A.D., Elisaf M. Effect of ezetimibe on lipoprotein subfraction concentrations: the role of atorvastatin pretreatment. Arch. Med. Sci. 2007, 3:344-350.
44. Kastelein J.J., Akdim F., Stroes E.S., Zwinderman A.H., Bots M.L., Stalenhoef A.F., Visseren F.L., Sijbrands E.J., Trip M.D., Stein E.A., Gaudet D., Duivenvoorden R., Veltri E.P., Marais A.D., de Groot E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 2008, 358:1431-1443.
45. Kielstein J.T., Frolich J.C., Haller H., Fliser D. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease?. Nephrol. Dial. Transplant. 2001, 16:1742-1745.
46. Kinlay S., Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am. J. Cardiol. 1997, 80:11I-16I.
47. Knopp R.H., Gitter H., Truitt T., Bays H., Manion C.V., Lipka L.J., LeBeaut A.P., Suresh R., Yang B., Veltri E.P. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur. Heart J. 2003, 24:729-741.
48. Kosoglou T., Statkevich P., Johnson-Levonas A.O., Paolini J.F., Bergman A.J., Alton K.B. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet. 2005, 44:67-94.
49. Kuhlencordt P.J., Padmapriya P., Rutzel S., Schodel J., Hu K., Schafer A., Huang P.L., Ertl G., Bauersachs J. Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Atherosclerosis 2009, 202:48-57.
50. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Despres J.P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69-75.
51. Lammert F., Wang D.Q.H. New insights into the genetic regulation of intestinal cholesterol absorbtion. Gastroenterology 2005, 129:718-734.
52. Lamon B.D., Hajjar D.P. Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am. J. Pathol. 2008, 173:1253-1264.
53. Landmesser U., Bahlmann F., Mueller M., Spiekermann S., Kirchhoff N., Schulz S., Manes C., Fischer D., de Groot K., Fliser D., Fauler G., Marz W., Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005, 111:2356-2363.
54. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 2005, 352:1425-1435.
55. Laufs U., Wassmann S., Hilgers S., Ribaudo N., Bohm M., Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am. J. Cardiol. 2001, 88:1306-1307.
56. Liu P.Y., Liu Y.W., Lin L.J., Chen J.H., Liao J.K. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009, 119:131-138.
57. Loirand G., Guerin P., Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. 2006, 98:322-334.
58. Luscher T.F., Barton M. Biology of the endothelium. Clin. Cardiol. 1997, 20(II):3-10.
59. Maki-Petaja K.M., Booth A.D., Hall F.C., Wallace S.M., Brown J., McEniery C.M., Wilkinson I.B. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J. Am. Coll. Cardiol. 2007, 50:852-858.
60. Mallika V., Goswami B., Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology 2007, 58:513-522.
61. Malmstrom R.E., Settergren M., Bohm F., Pernow J., Hjemdahl P. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance. Thromb. Haemost. 2009, 101:157-164.
62. Masuda D., Nakagawa-Toyama Y., Nakatani K., Inagaki M., Tsubakio-Yamamoto K., Sandoval J.C., Ohama T., Nishida M., Ishigami M., Yamashita S. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur. J. Clin. Invest. 2009, 39:689-698.
63. McKenney J.M. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am. J. Health Syst. Pharm. 2005, 62:1033-1047.
64. McKenney J.M., Farnier M., Lo K.W., Bays H.E., Perevozkaya I., Carlson G., Davies M.J., Mitchel Y.B., Gumbiner B. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J. Am. Coll. Cardiol. 2006, 47:1584-1587.
65. Meaney A., Ceballos G., Asbun J., Solache G., Mendoza E., Vela A., Meaney E. The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) study. J. Clin. Pharmacol. 2009, 49:838-847.
66. Melani L., Mills R., Hassman D., Lipetz R., Lipka L., LeBeaut A., Suresh R., Mukhopadhyay P., Veltri E. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur. Heart J. 2003, 24:717-728.
67. Meyers C.D., Moon Y.S., Ghanem H., Wong N.D. Type of preexisting lipid therapy predicts LDL-C response to ezetimibe. Ann. Pharmacother. 2006, 40:818-823.
68. Mikhailidis D.P., Wierzbicki A.S., Daskalopoulou S.S., Al-Saady N., Griffiths H., Hamilton G., Monkman D., Patel V., Pittard J., Schachter M. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr. Med. Res. Opin 2005, 21:959-969.
69. Nakagami H., Osako M.K., Takami Y., Hanayama R., Koriyama H., Mori M., Hayashi H., Shimizu H., Morishita R. Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis 2009, 203:51-58.
70. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Ueda Y., Suzuki T., Ueda S., Adachi H., Okuda S., Yamagishi S.I. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol. Res. 2009, 60:525-528.
71. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Ueda Y., Suzuki T., Ueda S., Fukami K., Okuda S., Yamagishi S.I. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol. Res. 2009, Electronic publication ahead of print.
72. Nakou E.S., Filippatos T.D., Georgoula M., Kiortsis D.N., Tselepis A.D., Mikhailidis D.P., Elisaf M.S. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr. Med. Res. Opin 2008, 24:1919-1929.
73. Nomura M., Ishii H., Kawakami A., Yoshida M. Inhibition of hepatic Neiman-Pick C1-Like 1 improves hepatic insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2009, Electronic publication ahead of print.
74. Nozaki Y., Fujita K., Yoneda M., Wada K., Shinohara Y., Takahashi H., Kirikoshi H., Inamori M., Kubota K., Saito S., Mizoue T., Masaki N., Nagashima Y., Terauchi Y., Nakajima A. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J. Hepatol. 2009, 51:548-556.
75. Oei H.H., van der Meer I.M., Hofman A., Koudstaal P.J., Stijnen T., Breteler M.M., Witteman J.C. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005, 111:570-575.
76. Olijhoek J.K., Hajer G.R., van der Graaf Y., Dallinga-Thie G.M., Visseren F.L. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J. Cardiovasc. Pharmacol. 2008, 52:145-150.
77. Ose L., Reyes R., Johnson-Levonas A.O., Sapre A., Tribble D.L., Musliner T. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin. Ther. 2007, 29:2419-2432.
78. Ostad M.A., Eggeling S., Tschentscher P., Schwedhelm E., Boger R., Wenzel P., Meinertz T., Munzel T., Warnholtz A. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis 2009, 205:227-232.
79. Pearson T.A., Ballantyne C.M., Veltri E., Shah A., Bird S., Lin J., Rosenberg E., Tershakovec A.M. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am. J. Cardiol. 2009, 103:369-374.
80. Piorkowski M., Fischer S., Stellbaum C., Jaster M., Martus P., Morguet A.J., Schultheiss H.P., Rauch U. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?. J. Am. Coll. Cardiol. 2007, 49:1035-1042.
81. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 2002, 347:1557-1565.
82. Rizzo M., Kotur-Stevuljevic J., Berneis K., Spinas G., Rini G.B., Jelic-Ivanovic Z., Spasojevic-Kalimanovska V., Vekic J. Atherogenic dyslipidemia and oxidative stress: a new look. Transl. Res. 2009, 153:217-223.
83. Rossebo A.B., Pedersen T.R., Boman K., Brudi P., Chambers J.B., Egstrup K., Gerdts E., Gohlke-Barwolf C., Holme I., Kesaniemi Y.A., Malbecq W., Nienaber C.A., Ray S., Skjaerpe T., Wachtell K., Willenheimer R. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 2008, 359:1343-1356.
84. Sager P.T., Capece R., Lipka L., Strony J., Yang B., Suresh R., Mitchel Y., Veltri E. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 2005, 179:361-367.
85. Salen G., von Bergmann K., Lutjohann D., Kwiterovich P., Kane J., Patel S.B., Musliner T., Stein P., Musser B. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004, 109:966-971.
86. Sane A.T., Sinnett D., Delvin E., Bendayan M., Marcil V., Menard D., Beaulieu J.F., Levy E. Localization and role of NPC1L1 in cholesterol absorption in human intestine. J. Lipid Res. 2006, 47:2112-2120.
87. Saougos V.G., Tambaki A.P., Kalogirou M., Kostapanos M., Gazi I.F., Wolfert R.L., Elisaf M., Tselepis A.D. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2236-2243.
88. Seedorf U., Engel T., Lueken A., Bode G., Lorkowski S., Assmann G. Cholesterol absorption inhibitor ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem. Biophys. Res. Commun. 2004, 320:1337-1341.
89. Settergren M., Bohm F., Ryden L., Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur. Heart J. 2008, 29:1753-1760.
90. Settergren M., Bohm F., Ryden L., Pernow J., Kalani M. Lipid lowering versus pleiotropic effects of statins on skin microvascular function in patients with dysglycaemia and coronary artery disease. J. Intern. Med. 2009, 266:492-498.
91. Shaw S.M., Najam O., Khan U., Yonan N., Williams S.G., Fildes J.E. Ezetimibe and atorvastatin both immunoregulate CD4+ T cells from cardiac transplant recipients invitro. Transpl. Immunol. 2009, 21:179-182.
92. Simon J.S., Karnoub M.C., Devlin D.J., Arreaza M.G., Qiu P., Monks S.A., Severino M.E., Deutsch P., Palmisano J., Sachs A.B., Bayne M.L., Plump A.S., Schadt E.E. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 2005, 86:648-656.
93. Solomon K.R., Pelton K., Boucher K., Joo J., Tully C., Zurakowski D., Schaffner C.P., Kim J., Freeman M.R. Ezetimibe is an inhibitor of tumor angiogenesis. Am. J. Pathol. 2009, 174:1017-1026.
94. Stampfer M.J., Krauss R.M., Ma J., Blanche P.J., Holl L.G., Sacks F.M., Hennekens C.H. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. J.A.M.A 1996, 276:882-888.
95. Staprans I., Pan X.M., Rapp J.H., Moser A.H., Feingold K.R. Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J. Lipid Res. 2006, 47:2575-2580.
96. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin. Invest. 1996, 97:2601-2610.
97. Sudhop T., Lutjohann D., Kodal A., Igel M., Tribble D.L., Shah S., Perevozskaya I., von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106:1943-1948.
98. Szeto W.Y., Krasinskas A.M., Kreisel D., Krupnick A.S., Popma S.H., Rosengard B.R. Depletion of recipient CD4+ but not CD8+ T lymphocytes prevents the development of cardiac allograft vasculopathy. Transplantation 2002, 73:1116-1122.
99. Taylor A.J., Villines T.C., Stanek E.J., Devine P.J., Griffen L., Miller M., Weissman N.J., Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 2009, 361:2113-2122.
100. Toth P.P., Davidson M.H. Cholesterol absorption blockade with ezetimibe. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2005, 5:455-462.
101. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med 1995, 332:481-487.
102. Trulock E.P., Christie J.D., Edwards L.B., Boucek M.M., Aurora P., Taylor D.O., Dobbels F., Rahmel A.O., Keck B.M., Hertz M.I. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J. Heart Lung Transplant. 2007, 26:782-795.
103. Tselepis A.D., Chapman M.J. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler. Suppl. 2002, 3:57-68.
104. Turk T.R., Voropaeva E., Kohnle M., Nurnberger J., Philipp T., Kribben A., Heemann U., Witzke O. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol. Dial. Transplant 2008, 23:369-373.
105. Yu L., Bharadwaj S., Brown J.M., Ma Y., Du W., Davis M.A., Michaely P., Liu P., Willingham M.C., Rudel L.L. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J. Biol. Chem. 2006, 281:6616-6624.
106. Westerweel P.E., Visseren F.L., Hajer G.R., Olijhoek J.K., Hoefer I.E., de Bree P., Rafii S., Doevendans P.A., Verhaar M.C. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. Eur. Heart J. 2008, 29:2808-2817.
107. Wierzbicki A.S., Doherty E., Lumb P.J., Chik G., Crook M.A. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr. Med. Res. Opin 2005, 21:333-338.
108. Winkler K., Schewe T., Putz G., Odunc N., Schafer G., Siegel E., Geisen U., Abletshauser C., Hoffmann M.M. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur. J. Clin. Invest 2009, 39:463-470.
109. Zheng S., Hoos L., Cook J., Tetzloff G., Davis H., van Heek M., Hwa J.J. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur. J. Pharmacol. 2008, 584:118-124.